Investor profile
Omega Funds has backed 10 European tech companies across 12 funding rounds between 2020 and 2026, joining rounds totalling €539M. Most active in Healthtech and Edtech. Data as of 4 Aug 2026.
Also recorded as: Omega · Omega Venture Partners · Omega Ventures
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Artios | UK | 2 | €229M |
| NRG Therapeutics | UK | 2 | €76M |
| EyeBiotech | UK | 1 | €61M |
| SoniVie | Italy | 1 | €56M |
| Anjarium Biosciences | Switzerland |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Artios | Series C | €130M | 2021-07 |
| Artios | Series D+ | €99M | 2025-11 |
| EyeBiotech | Series A | €61M | 2023-11 |
| NRG Therapeutics |
| 1 |
| €51M |
| eTheRNA | Belgium | 1 | €39M |
| Chord Therapeutics | Switzerland | 1 | €14M |
| Treble Technologies | Iceland | 1 | €11M |
| Aavalynx | Finland | 1 | €1.8M |
| Evolytes | Iceland | 1 | €1.3M |
| Series B |
| €58M |
| 2025-09 |
| SoniVie | Series C | €56M | 2023-01 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| eTheRNA | Series B | €39M | 2022-08 |
| NRG Therapeutics | Series A | €18M | 2022-11 |
| Chord Therapeutics | Series A | €14M | 2020-10 |
| Treble Technologies | Series A | €11M | 2024-09 |
